Clinical trial · Interventional
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer
NCT00378066CI-TRIAL-00009049completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- ACTIVE_COMPARATOR
- label
- Bevacizumab
- description
- Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- time to progression
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
- overall survival, safety, response
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically documented colorectal adenocarcinoma * ECOG performance status of 2 or lower * Adequate bone marrow function * Adequate kidney function * Adequate liver function * Informed consent Exclusion Criteria: * Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start * Known allergy to study drugs
References
Publications (0)
Data not yet available
No reference posted for this study.